BC Extra | Jun 15, 2019
Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
BC Week In Review | Sep 21, 2018
Company News

Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Sept. 20 that partner Celgene Corp. (NASDAQ:CELG) will not exercise its option to license OncoMed's bispecific antibody navicixizumab (OMP-305B83) as a result of "strategic product portfolio considerations." The bispecific targeting...
BC Innovations | Jul 12, 2018
Translation in Brief

Reviving NK cells

Researchers from the University of Science and Technology of China have identified a key role for TIGIT in NK cell exhaustion that suggests immunotherapies targeting TIGIT may be useful against cancers that have failed to...
BioCentury | Jan 27, 2018
Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
BC Week In Review | May 12, 2017
Clinical News

OncoMed starts Phase Ia of anti-TIGIT antibody to treat solid tumors

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) began a Phase Ia trial evaluating OMP-313M32 to treat advanced or metastatic solid tumors. The open-label, dose-escalation, U.S. trial will evaluate IV OMP-313M32 every 2 weeks in about 30 patients. The...
Items per page:
1 - 5 of 5